1313040-41-3

Upstream product

• 696-60-6 4-aminomethylphenol 
• 63491-89-4 4-(aminomethyl)-2-bromophenol hydrogenbromide salt 
• 1313042-26-0 tert-butyl N-[(3-bromo-4-hydroxyphenyl)methyl]carbamate 
• 1313042-27-1 [2-bromo-4-(tert-butoxycarbonylamino-methyl)-phenoxy]-acetic acid methyl ester 
• 1313042-28-2 [4-(tert-butoxycarbonylamino-methyl)-2-pyridin-4-yl-phenoxy]-acetic acid methyl ester 
• 1313042-29-3 [4-(tert-butoxycarbonylamino-methyl)-2-piperidin-4-yl-phenoxy]-acetic acid methyl ester 
• 1313042-30-6 (4-(tert-butoxycarbonylamino-methyl)-2-{1-[1-(2-methoxy-ethyl)-7-methyl-1H-indole-3-carbonyl]-piperidin-4-yl}-phenoxy)-acetic acid methyl ester 
• 1313042-37-3 (3-{1-[1-(2-methoxy-ethyl)-7-methyl-1H-indole-3-carbonyl]-piperidin-4-yI}-4-methylcarbamoyl methoxy-benzyl )-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS

The present invention discloses and claims a series of substituted indolyl-piperidinyl benzylamines of formula (I), wherein R1, R2 and R3 are as described herein. More specifically, the compounds of this invention are inhibitors of β-tryptase and are, therefore, useful as pharmaceutical agents. Additionally, this invention also discloses methods of preparation of substituted indolyl-piperidinyl benzylamines. In one of the embodiments, there is provided the compounds of formula (I) wherein R3 is (II).